Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level.
Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level.
复制标题
DOI：
10.1016/j.ebiom.2023.104545
复制
发表时间：
2023-04
期刊：
影响因子：
11.1
通讯作者：
Turville, Stuart G.
中科院分区：
文献类型：
--
作者：
Akerman, Anouschka;Milogiannakis, Vanessa;Jean, Tyra;Esneau, Camille;Silva, Mariana Ruiz;Ison, Timothy;Fichter, Christina;Lopez, Joseph A.;Chandra, Deborah;Naing, Zin;Caguicla, Joanna;Li, Daiyang;Walker, Gregory;Amatayakul-Chantler, Supavadee;Roth, Nathan;Manni, Sandro;Hauser, Thomas;Barnes, Thomas;Condylios, Anna;Yeang, Malinna;Wong, Maureen;Foster, Charles S. P.;Sato, Kenta;Lee, Sharon;Song, Yang;Mao, Lijun;Sigmund, Allison;Phu, Amy;Vande More, Ann Marie;Hunt, Stephanie;Douglas, Mark;Caterson, Ian;Britton, Warwick;Sandgren, Kerrie;Bull, Rowena;Lloyd, Andrew;Triccas, Jamie;Tangye, Stuart;Bartlett, Nathan W.;Darley, David;Matthews, Gail;Stark, Damien J.;Petoumenos, Kathy;Rawlinson, William D.;Murrell, Ben;Brilot, Fabienne;Cunningham, Anthony L.;Kelleher, Anthony D.;Aggarwal, Anupriya;Turville, Stuart G.
COVID-19疫情的Omicron时代始于二零二二年初，虽然最初主要以BA. 1为主，但其后以BA. 2及相关亚系BA. 5为主。随着全球BA.5浪潮的消退，出现了源自BA.2、BA.5及其重组体的一组不同的Omicron亚谱系。虽然来自不同的谱系，但所有的刺突糖蛋白都有相似的变化，通过逃避中和抗体使它们具有生长优势。在2022年期间，我们在三个层面监测了澳大利亚社区对许多新出现的变体的抗体中和反应的效力和广度：（i）我们通过各种疫苗加强剂的推出和Omicron波，使用顺序收集的IgG池，随着时间的推移追踪了超过420，000名美国血浆供体;（ii）我们使用来自严格管理的疫苗和康复期队列的血液绘制了个体中的抗体应答。(iii)最后，我们确定了临床批准的治疗Evusheld和Sotrovimab的体外功效。在合并的IgG样本中，我们观察到通过持续的疫苗和感染波，随着时间的推移，对Omicron变体的中和宽度逐渐成熟。重要的是，在许多情况下，我们观察到针对尚未进入流通的变体的抗体宽度增加。队列水平的病毒中和测定支持既往和新出现的变异体之间的覆盖率相等，分离株BQ.1.1、XBB.1、BR.2.1和XBF最具逃避性。此外，这些新出现的变体对Evushold具有耐药性，而对Sotrovimab的中和耐药性增加仅限于BQ.1.1和XBF。我们得出结论，在目前的时间点，显性变异可以逃避抗体的水平相当于他们最逃避谱系对应，但维持进入表型，继续促进额外的生长优势。在澳大利亚，BR.2.1和XBF具有相同的表型，与全球变体相比，它们在2022年的后几个月在该地区具有独特的优势。虽然多种omicron谱系的出现导致了对临床批准的单克隆抗体的原发性或部分耐药，但重要的是，两个队列和大型供体库中抗体应答的成熟观察到抗体中和应答随时间的宽度增加，其轨迹涵盖了当前和已知的新出现的变体。这项工作主要由研究赠款MRF 2005760（SGT，GM & WDR），补助金（WDR），（SGT & FB）和（VIIM）（ALC）支持。变体建模得到了SciLifeLab的流行病实验室准备计划向B.M.（VC-2022-0028）和欧盟的地平线2020研究和创新计划根据赠款协议编号101003653（CoroNAb）授予B.M.
The Omicron era of the COVID-19 pandemic commenced at the beginning of 2022 and whilst it started with primarily BA.1, it was latter dominated by BA.2 and the related sub-lineage BA.5. Following resolution of the global BA.5 wave, a diverse grouping of Omicron sub-lineages emerged derived from BA.2, BA.5 and recombinants thereof. Whilst emerging from distinct lineages, all shared similar changes in the Spike glycoprotein affording them an outgrowth advantage through evasion of neutralising antibodies. Over the course of 2022, we monitored the potency and breadth of antibody neutralization responses to many emerging variants in the Australian community at three levels: (i) we tracked over 420,000 U.S. plasma donors over time through various vaccine booster roll outs and Omicron waves using sequentially collected IgG pools; (ii) we mapped the antibody response in individuals using blood from stringently curated vaccine and convalescent cohorts. (iii) finally we determine the in vitro efficacy of clinically approved therapies Evusheld and Sotrovimab. In pooled IgG samples, we observed the maturation of neutralization breadth to Omicron variants over time through continuing vaccine and infection waves. Importantly, in many cases, we observed increased antibody breadth to variants that were yet to be in circulation. Determination of viral neutralization at the cohort level supported equivalent coverage across prior and emerging variants with isolates BQ.1.1, XBB.1, BR.2.1 and XBF the most evasive. Further, these emerging variants were resistant to Evusheld, whilst increasing neutralization resistance to Sotrovimab was restricted to BQ.1.1 and XBF. We conclude at this current point in time that dominant variants can evade antibodies at levels equivalent to their most evasive lineage counterparts but sustain an entry phenotype that continues to promote an additional outgrowth advantage. In Australia, BR.2.1 and XBF share this phenotype and, in contrast to global variants, are uniquely dominant in this region in the later months of 2022. Whilst the appearance of a diverse range of omicron lineages has led to primary or partial resistance to clinically approved monoclonal antibodies, the maturation of the antibody response across both cohorts and a large donor pools importantly observes increasing breadth in the antibody neutralisation responses over time with a trajectory that covers both current and known emerging variants. This work was primarily supported by research grants MRF2005760 (SGT, GM & WDR), grant (WDR), the (SGT & FB) and the (VIIM) (ALC). Variant modeling was supported by funding from SciLifeLab's Pandemic Laboratory Preparedness program to B.M. (VC-2022-0028) and by the European Union's Horizon 2020 research and innovation programme under grant agreement no. 101003653 (CoroNAb) to B.M.
登录
查看更多内容
影响因子：
64.8
作者：
Barnes CO;Jette CA;Abernathy ME;Dam KA;Esswein SR;Gristick HB;Malyutin AG;Sharaf NG;Huey-Tubman KE;Lee YE;Robbiani DF;Nussenzweig MC;West AP Jr;Bjorkman PJ
通讯作者：
Bjorkman PJ
影响因子：
56.9
作者：
McCallum, Matthew;Czudnochowski, Nadine;Rosen, Laura E.;Zepeda, Samantha K.;Bowen, John E.;Walls, Alexandra C.;Hauser, Kevin;Joshi, Anshu;Stewart, Cameron;Dillen, Josh R.;Powell, Abigail E.;Croll, Tristan, I;Nix, Jay;Virgin, Herbert W.;Corti, Davide;Snell, Gyorgy;Veesler, David
通讯作者：
Veesler, David
DOI：
10.1152/ajplung.00374.2020
发表时间：
2020-12-01
影响因子：
4.9
作者：
Loo, Su-Ling;Wark, Peter A. B.;Bartlett, Nathan W.
通讯作者：
Bartlett, Nathan W.
影响因子：
11.1
作者：
Aggarwal, Anupriya;Akerman, Anouschka;Milogiannakis, Vanessa;Silva, Mariana Ruiz;Walker, Gregory;Stella, Alberto Ospina;Kindinger, Andrea;Angelovich, Thomas;Waring, Emily;Amatayakul-Chantler, Supavadee;Roth, Nathan;Manni, Sandro;Hauser, Thomas;Barnes, Thomas;Condylios, Anna;Yeang, Malinna;Wong, Maureen;Jean, Tyra;Foster, Charles S. P.;Christ, Daniel;Hoppe, Alexandra Carey;Munier, Mee Ling;Darley, David;Churchill, Melissa;Stark, Damien J.;Matthews, Gail;Rawlinson, William D.;Kelleher, Anthony D.;Turville, Stuart G.
通讯作者：
Turville, Stuart G.
影响因子：
64.8
作者：
Mlcochova P;Kemp SA;Dhar MS;Papa G;Meng B;Ferreira IATM;Datir R;Collier DA;Albecka A;Singh S;Pandey R;Brown J;Zhou J;Goonawardane N;Mishra S;Whittaker C;Mellan T;Marwal R;Datta M;Sengupta S;Ponnusamy K;Radhakrishnan VS;Abdullahi A;Charles O;Chattopadhyay P;Devi P;Caputo D;Peacock T;Wattal C;Goel N;Satwik A;Vaishya R;Agarwal M;Indian SARS-CoV-2 Genomics Consortium (INSACOG);Genotype to Phenotype Japan (G2P-Japan) Consortium;CITIID-NIHR BioResource COVID-19 Collaboration;Mavousian A;Lee JH;Bassi J;Silacci-Fegni C;Saliba C;Pinto D;Irie T;Yoshida I;Hamilton WL;Sato K;Bhatt S;Flaxman S;James LC;Corti D;Piccoli L;Barclay WS;Rakshit P;Agrawal A;Gupta RK
通讯作者：
Gupta RK